日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

管腔乳腺癌的身份取决于糖皮质激素受体活性的丧失

Stefan Prekovic #, Theofilos Chalkiadakis #, Merel Roest #, Daniel Roden, Catrin Lutz, Karianne Schuurman, Mark Opdam, Liesbeth Hoekman, Nina Abbott, Tanja Tesselaar, Maliha Wajahat, Amy R Dwyer, Isabel Mayayo-Peralta, Gabriela Gomez, Maarten Altelaar, Roderick Beijersbergen, Balázs Győrffy, Leonie

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer

雄激素受体是雌激素受体阳性乳腺癌的肿瘤抑制因子

Theresa E Hickey, Luke A Selth, Kee Ming Chia, Geraldine Laven-Law, Heloisa H Milioli, Daniel Roden, Shalini Jindal, Mun Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen N Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C Elizabeth Caldon, Tarek M Abdel-Fatah, Ian O Ellis, Wilbert Zwa

Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions

HER2 阳性乳腺癌的空间反卷积描绘了肿瘤相关细胞类型的相互作用

Alma Andersson #, Ludvig Larsson #, Linnea Stenbeck #, Fredrik Salmén, Anna Ehinger, Sunny Z Wu, Ghamdan Al-Eryani, Daniel Roden, Alex Swarbrick, Åke Borg, Jonas Frisén, Camilla Engblom, Joakim Lundeberg

Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB

分化抑制剂 4 (ID4) 通过抑制 HEB 来抑制乳腺肌上皮分化

Holly Holliday, Daniel Roden, Simon Junankar, Sunny Z Wu, Laura A Baker, Christoph Krisp, Chia-Ling Chan, Andrea McFarland, Joanna N Skhinas, Thomas R Cox, Bhupinder Pal, Nicholas D Huntington, Christopher J Ormandy, Jason S Carroll, Jane Visvader, Mark P Molloy, Alexander Swarbrick

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

基底样乳腺癌分化抑制剂 4 (ID4) 的蛋白质组学分析

Laura A Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z Wu, Simon Junankar, Aurelien A Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M K Law, Andrea McFarland, Peter T Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger, Lyndal Anderson, Goli Samimi, Nev

Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes

对社论“COVID-19 与心血管疾病患者”的回应:使用羟氯喹或氯喹联合阿奇霉素治疗 COVID-19:尖端扭转型室性心动过速的潜在风险

Funck-Brentano, Christian; Salem, Joe-Elie; Nguyen, Lee S; Drici, Milou-Daniel; Roden, Dan M

High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes

高通量靶向长读长单细胞测序揭示淋巴细胞的克隆和转录图谱

Mandeep Singh ,Ghamdan Al-Eryani ,Shaun Carswell ,James M Ferguson ,James Blackburn ,Kirston Barton ,Daniel Roden ,Fabio Luciani ,Tri Giang Phan ,Simon Junankar ,Katherine Jackson ,Christopher C Goodnow ,Martin A Smith ,Alexander Swarbrick

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

由胰腺癌细胞 p53 状态驱动的 CAF 层次结构通过基底膜蛋白聚糖创造了促转移和化学抗性的环境

Claire Vennin, Pauline Mélénec, Romain Rouet, Max Nobis, Aurélie S Cazet, Kendelle J Murphy, David Herrmann, Daniel A Reed, Morghan C Lucas, Sean C Warren, Zehra Elgundi, Mark Pinese, Gabriella Kalna, Daniel Roden, Monisha Samuel, Anaiis Zaratzian, Shane T Grey, Andrew Da Silva, Wilfred Leung; Austr

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

靶向基质重塑和癌症干细胞可塑性可克服三阴性乳腺癌的化学耐药性

Aurélie S Cazet, Mun N Hui, Benjamin L Elsworth, Sunny Z Wu, Daniel Roden, Chia-Ling Chan, Joanna N Skhinas, Raphaël Collot, Jessica Yang, Kate Harvey, M Zahied Johan, Caroline Cooper, Radhika Nair, David Herrmann, Andrea McFarland, Niantao Deng, Manuel Ruiz-Borrego, Federico Rojo, José M Trigo, Sus